Research map: Treatment patterns in homozygous familial hypercholesterolemia: Undertreatment and delayed adoption of low-density lipoprotein receptor–independent therapies

Back to the article

Papers in this map

  1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel · Brian A. Ference · 2017 · 4033 citations · Cited by this paper
  2. Impact of High-sensitivity C-reactive protein testing on statin use in primary prevention: A national multicenter analysis · 2026 · Related
  3. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society · M. Cuchel · 2014 · 1077 citations · Cited by this paper
  4. Association of reproductive factors with acute myocardial infarction in young women: A VIRGO and NHANES case-control study · 2026 · Related
  5. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance · Marina Cuchel · 2023 · 364 citations · Cited by this paper
  6. Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program · 2026 · Related
  7. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement · Nathan D. Wong · 2022 · 303 citations · Cited by this paper
  8. Beyond place: Neighborhood deprivation, cardiometabolic health, and the life course origins of hypertensive disorders of pregnancy · 2026 · Related
  9. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study · Tycho R. Tromp · 2022 · 217 citations · Cited by this paper
  10. Absence of significant coronary artery disease does not eliminate smoking-related cardiovascular risk: insights from the PROMISE trial · 2026 · Related
  11. Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia · Anthony Wang · 2016 · 107 citations · Cited by this paper
  12. Don’t sleep on the other beds: Atherosclerosis across heart, brain, and limbs · 2026 · Related
  13. Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association · Eugenia Gianos · 2024 · 76 citations · Cited by this paper
  14. Prevalence and predictors of silent atherosclerosis across life: Design of the REACT Phase 1 study · 2026 · Related
  15. Epidemiology of familial hypercholesterolaemia: Community and clinical · Antonio J. Vallejo‐Vaz · 2018 · 60 citations · Cited by this paper
  16. Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral center · 2026 · Related
  17. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry · Marina Cuchel · 2023 · 55 citations · Cited by this paper
  18. Effectiveness of Yoga-based guided meditation In Improving the quality of sleep in patients with coronary artery disease: The Yoga Nidra Trial · 2026 · Related
  19. Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary · Jing Gu · 2024 · 28 citations · Cited by this paper
  20. The Coverage Gap in PREVENT: Why Cardiovascular Risk Prediction Needs a Lab-Free Complement · 2026 · Related
  21. Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association · Zahid Ahmad · 2026 · 25 citations · Cited by this paper
  22. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia · Archna Bajaj · 2022 · 23 citations · Cited by this paper
  23. It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States · Samuel S. Gidding · 2024 · 16 citations · Cited by this paper
  24. Novel therapies for familial hypercholesterolemia · Farzahna Mohamed · 2020 · 12 citations · Cited by this paper
  25. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis · Awad Saad Alshahrani · 2024 · 8 citations · Cited by this paper
  26. High burden of disease in patients with homozygous familial hypercholesterolemia despite recent advances in therapies and updated guidelines: A real-world study · Jing Gu · 2025 · 5 citations · Cited by this paper
  27. Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype · G.B. John Mancini · 2026 · 2 citations · Cited by this paper
  28. Homozygous familial hypercholesterolaemia: insights from the Global HICC Registry · Willemijn A. M. Schonck · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)